Loading...
•
Sep 30, 2023
Curis Q3 2023 Earnings Report
Curis reported financial results for the third quarter of 2023, showing a net loss, revenue from royalties, and progress in clinical trials for Emavusertib.
Key Takeaways
Curis, Inc. reported a net loss of $12.2 million for Q3 2023, with revenues of $2.8 million from royalties. The company is advancing its clinical development of emavusertib, with ongoing trials and upcoming data presentations.
Re-started patient enrollment in both the Phase 1/2 TakeAim Leukemia monotherapy and TakeAim Lymphoma combination studies after the removal of the partial clinical hold.
Expects to initiate a triplet combination study in AML in the fourth quarter.
Will present updated data from the TakeAim Lymphoma combination study at ASH in December.
Cash, cash equivalents and investments totaled $68.5 million, expected to fund operations into 2025.
Forward Guidance
Curis expects its existing cash, cash equivalents and investments to enable its planned operations into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...